Towards a Cure for Acute Myeloid Leukemia by combining Epigenetics and Stem Cell Transplantation
Presentation by Dr. Tobias Berg, Associate Professor in the Department of Oncology, McMaster University, Regional Respirology Rounds, Division of Respirology, January 12th, 2021
Learning Objectives:
- To introduce Acute Myeloid Leukemia as a Model Disease and the role of allogeneic stem cell transplantation in its treatment
- To give an overview of the heterogeneity of AML and determinants of treatment success
- To summarize the role of LSD1, an emerging epigenetic target in the treatment of AML, and its interplay with cellular differentiation, metabolism and the immune response
Dr. Berg is a clinician scientist and joined McMaster University as an Associate Professor in the Department of Oncology in 2019. He holds the Boris Family Chair in Leukemia and Hematopoietic Stem Cell Translational Research. His clinical focus as a Hematologist is on allogeneic stem cell transplantation and cellular therapies in particular in the treatment of acute leukemias. His research is centred around understanding determinants of treatment response in AML with a focus on epigenetic regulation.
Before coming to McMaster University Dr. Berg worked as a Hematologist and Medical Oncologist at the University of Frankfurt, Germany. He studied medicine in Rostock, Homburg, Minneapolis and Freiburg where he graduated in 2004 and received his Doctoral Degree in 2005. He did his clinical training in Internal Medicine, Hematology and Oncology in Freiburg and Frankfurt. From 2008 - 2011, he was a postdoctoral fellow at the Terry-Fox-Laboratory in Vancouver, Canada.
Copyright McMaster University 2021
-
Category
No comments found